Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

Betty Mwesigwa, Katherine V. Houser, Amelia R. Hofstetter, Ana M. Ortega‐Villa, Prossy Naluyima, Francis Kiweewa, Immaculate Nakabuye, Galina V. Yamshchikov, Charla Andrews, Mark O’Callahan, Larisa Strom, Steven Schech, Leigh Anne Eller, Erica L Sondergaard, Paul T. Scott, Mihret F. Amare, Kayvon Modjarrad, Amir Wamala, Allan Tindikahwa, Ezra Musingye, Jauhara Nanyondo, Martin R. Gaudinski, Ingelise J. Gordon, LaSonji A. Holman, Jamie Saunders, Pamela Costner, Floreliz Mendoza, Myra Happe, Patricia Morgan, Sarah H. Plummer, Somia P. Hickman, Sandra Vazquez, Tamar Murray, Jamilet Cordon, Caitlyn N M Dulan, Ruth Hunegnaw, Manjula Basappa, Marcelino Padilla, Suprabhath Gajjala, Phillip A. Swanson, Bob C. Lin, Emily E. Coates, Jason G. Gall, Adrian B. McDermott, Richard A. Koup, John R. Mascola, Aurélie Ploquin, Nancy J. Sullivan, Hannah Kibuuka, Julie A. Ake, Julie E. Ledgerwood, Jaqueline Namugabo, Claire Beingana, Maureen G. Mukyala, Joseph Wandege, Christine Nanteza, Brenda Atwijuka, Juliet Kizanye, Gertrude Nassanga, Joanita Namuli, Herbert Kityo, Mathias Ssekitoleko, Roy Nassaka, Hilda Mutebe, Mable Kabahubya, Alicia T. Widge, Sarah O’Connell, Obrimpong Amoa-Awua, Sandeep Narpala, Britta Flach, Josephine H. Cox, Allison Beck, Mercy Guech, Ellie Seo, Judy Stein